Patents Assigned to Sami Labs Limited
  • Patent number: 11197898
    Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: December 14, 2021
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Furqan Ali, Sivakumar Arumugam, Shaheen Majeed, Kirankumar Beede
  • Patent number: 10898536
    Abstract: The invention discloses the anti-acne potential of ? and ? pyranocycloartobiloxanthone A and Artonine E, isolated from the stem bark of Artocarpus hirsutus by inhibiting the growth of Propionibacterium acnes.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 26, 2021
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Mahadeva Nayak, Nagarajan Ananthanarayanan
  • Patent number: 9498423
    Abstract: The present invention discloses selenium peptide based synergistic compositions for the protection (morphology and viable numbers) of dermal papilla cells. The synergistic compositions disclosed in the present invention comprise (a) 1-O-galloyl-?-D-glucose (?-glucogallin) or 1-O-galloyl-?-D-glucose (?-glucogallin) and gallates (b) concentrate of liquid endosperm of Cocos nucifera and (c) selenopeptides.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: November 22, 2016
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 9056074
    Abstract: A novel, bioavailable and safe stilbenoid 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#1 with an unexpected enhanced ability to prevent the accumulation of lipids accompanying the terminal differentiation of adipocytes, thereby inhibiting adipogenesis, and nutraceutical and cosmeceutical compositions comprising 3,5-dimethoxy-3,4?-dihydroxystilbene useful for anti-obesity and anti-cellulite therapy, are disclosed. Further the enhanced SIRT-1 activation ability of 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#1 and 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II are disclosed. The enhancement of SIRT-1 polypeptide activity of the said compounds is unexpectedly much higher than resveratrol or its natural analog pterostilbene. Sirtuin modulating compositions comprising an orally bioavailable SIRT-1 enhancing compounds (i) 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I and (ii) 2,3?,5?,6-tetrahydroxy-trans-stilbene represented by STR#II are also disclosed.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: June 16, 2015
    Assignee: Sami Labs Limited
    Inventors: Krishnamani Jayaraman, Muhammed Majeed, Jeffrey Reinhardt, Kalyanam Nagabhushanam, Samuel Manoharan Thomas
  • Patent number: 9050284
    Abstract: Disclosed is a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 3,5-dimethoxy-3,4?-dihydroxystilbene represented by STR#I. Also disclosed is an anti-acne composition comprising 3,5-dimethoxy-3,4?-dihydroxystilbenes represented by STR#I. Further, a novel sirtuin modulating composition comprising an orally bioavailable SIRT-1 enhancing compound 2,3?,5?, 6-tetrahydroxy-trans-stilbene represented by STR#II is also disclosed.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: June 9, 2015
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Jeffrey Reinhardt, Kalyanam Nagabhushanam, Samuel Manoharan Thomas, Krishnamani Jayaraman
  • Patent number: 8933121
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: January 13, 2015
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Anjali Pandey
  • Patent number: 8383594
    Abstract: The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: February 26, 2013
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Renukeshwar H Chandramouli, Kalyanam Nagabhushanam, Rattan Sood, Subbalakshmi Prakash, Susmitha Anand
  • Patent number: 8329095
    Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: December 11, 2012
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Beena Bhat, Garima Agarwal
  • Patent number: 8329743
    Abstract: The present invention provides a composition comprising polyisoprenylated benzophenone derivative and at least one component selected from stilbene derivative and anthocyanins. The composition inhibits adipogenesis and is therefore useful in treating obesity or weight loss.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: December 11, 2012
    Assignee: Sami Labs Limited
    Inventor: Muhammed Majeed
  • Patent number: 7378442
    Abstract: The invention relates to methods of treatment and pharmaceutical compositions of new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: May 27, 2008
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabushnam, Rajendran Ramanujam, Subbalakshmi Prakash
  • Patent number: 7371889
    Abstract: The invention relates to new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.
    Type: Grant
    Filed: March 11, 2007
    Date of Patent: May 13, 2008
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagebhuananam, Rajendran Ramanujam, Subbalakshmi Prakash
  • Patent number: 7253324
    Abstract: Alkoxy aromatic compounds are conveniently dealkylated to the corresponding phenolic compounds by treatment with aluminum chloride/N,N-dimethyl aniline complex. Aromatic poly O-demethylation is a unique feature of this invention. This process is applicable to the manufacture of polyphenols such as Resveratrol, Oxyresveratrol, Gnetol.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: August 7, 2007
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Samuel Manoharan Thomas, Kalyanam Nagabhushanam, Sivaprakash Kurumanghat Balakrishnan, Subbalakshmi Prakash
  • Patent number: 7202270
    Abstract: A process for the manufacture of new crystalline salts of N-[2-(dimethylamino)ethyl]-1,2-dithiolane-3-pentanamide (racemic and chiral forms) is described. Such salts are stable, crystalline and have very good solubility in water. The salts exhibit antioxidant properties. They inhibit collagenase and elastase enzymes. They have excellent anti acne activity in addition tyrosinase inhibition. They are, by themselves and in combination with other known agents, important cosmetic ingredients.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: April 10, 2007
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam
  • Patent number: 7160562
    Abstract: The invention describes compositions and methods containing nonconventional plant materials, and more particularly the species Flemingia macrophylla and Careya arborea, that help to maintain normal blood sugar levels in humans and animals. The method of preparation of such compositions and methods of quantifying active principles therein are also described. A Metformin-like compound were found to be the active hypoglycemic principle in Flemingia macrophylla and Careya arborea root bark. The compositions of the invention were found to be safe for therapeutic use.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: January 9, 2007
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Subbalakshmi Prakash, Shipra Roy, Venu Agarwal
  • Patent number: 7014874
    Abstract: The invention discloses a method to prepare concentrates from Allium sativum Linn. (Garlic) bulbs naturally enriched with an unique composition of organic selenium compounds and the use of such concentrates in nutritional supplement compositions for human and animal use. The resulting compositions provide a safe and efficacious means of providing supplemental amounts of the essential trace mineral nutrient selenium for diverse health benefits.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: March 21, 2006
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Rajinder Kumar Bammi, Vladimir Badmaev, Subbalakshmi Prakash, Nagabhushanam Kalyanam
  • Patent number: 6960300
    Abstract: Aqueous solutions of diterpenes such as Forskolin, its congeners, analogs and derivatives, up to approximately 6% concentration, are prepared using suitably substituted cyclodextrin as a solubilizing agents. In the absence of cyclodextrin, some diterpenes such as Forskolin are soluble in water only to concentrations of about 0.001%. Such aqueous solutions find applications in topical and systemic use, as pharmaceutical, cosmeceutical, nutraceutical preparations containing diterpenes such as Forskolin and congeners.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: November 1, 2005
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Arvind Kumar, Kalyanam Nagabhushanam, Subbalakshmi Prakash
  • Patent number: 6794537
    Abstract: Convenient processes are described for the synthesis of L-Se-methyselenocysteine from chloroalanine derivatives. The process is easily extendable to other selenium substituted amino acids. DL-Se-methyselenocysteine is easily obtained by a benzaldehyde-catalyzed racemization of L-Se-methyselenocysteine.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: September 21, 2004
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Rajendran Ramanujam, Ravikrishna Chebolu, Keshava Rapole